During a conference call with analysts on Pfizer Inc.'s fourth-quarter results, executives of the drugmaker were asked about plans to acquire new businesses, even as the drug giant has been streamlining to cut costs and divest noncore businesses. Chief Financial Officer Frank D'Amelio outlined what the drugmaker might be looking for.
Question: What's your philosophy on deals? Any plans for a big acquisition?
Answer: Our focus has been and continues to be bolt-on acquisitions. ... Our priorities remain our focused therapeutic and disease areas (such as cancer and heart disease).